Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-04-10 | Ascelia Pharma | Ascelia Pharma Reports SPARKLE Image Reading Completion and Expects Headline Results First Half of May 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-10 | Ascelia Pharma | Ascelia Pharma rapporterar att SPARKLE-bildläsningsfasen är avslutad och förväntar sig headline-resultat i första halvan av maj 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-08 | Ascelia Pharma | Årsredovisning 2023: Solida framsteg med slutförd patientrekrytering till Orviglance fas 3 och förväntat headline-resultat i maj 2024 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-04-08 | Ascelia Pharma | Annual Report 2023: Solid Progress with Orviglance Phase 3 Patient Recruitment Completed and Headline Results Expected by May 2024 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-03-27 | Ascelia Pharma | Notice of Annual General Meeting in Ascelia Pharma AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-27 | Ascelia Pharma | Kallelse till årsstämma i Ascelia Pharma AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-21 | Penser Access by Carnegie | Penser Access by Carnegie: Interview with Ascelia Pharma - Carnegie Investment Bank - Feb 21th 2024 | Pressreleaser | Visa Stäng |
|
||||
2024-02-12 | Penser Access by Carnegie | Penser Access by Carnegie: Ascelia Pharma - Finansiering på plats, avgörande data i maj | Pressreleaser | Visa Stäng |
|
||||
2024-02-12 | Redeye | Redeye: Ascelia Pharma Q4 2023 - On track with easing financial pressure | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-09 | Ascelia Pharma | Q4 and Full Year Report 2023: Strengthened Financial Position Ahead of SPARKLE Phase 3 Study Headline Results in May | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-09 | Ascelia Pharma | Q4 och bokslutskommuniké 2023: Stärkt finansiell position inför headline-resultat i maj för den kliniska fas-3 studien SPARKLE | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-04 | Ascelia Pharma | Ascelia Pharma säkrar finansiering om upp till 35 MSEK | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-04 | Ascelia Pharma | Ascelia Pharma Secures Financing of up to SEK 35 Million | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-24 | Ascelia Pharma | Orviglance Review Article Published in Investigative Radiology | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-24 | Ascelia Pharma | Översiktsartikel om Orviglance publicerad i Investigative Radiology | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-24 | Ascelia Pharma | Nomination Committee Appointed for AGM 2024 in Ascelia Pharma AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-24 | Ascelia Pharma | Valberedning utsedd i Ascelia Pharma AB inför årsstämman 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-07 | Ascelia Pharma | Ascelia Pharma Announces Start of Image Reading Phase and Re-confirms Phase 3 SPARKLE Results by May 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-07 | Ascelia Pharma | Ascelia Pharma meddelar start av bildläsningsfasen och bekräftar resultat från fas 3 SPARKLE senast i maj 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-06 | Finansinspektionen | Finansinspektionen: Flaggningsmeddelande i Ascelia Pharma AB | Pressreleaser | Visa Stäng |
|
||||
2023-11-30 | Ascelia Pharma | Change in Number of Shares and Votes in Ascelia Pharma AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-30 | Ascelia Pharma | Ändring av antalet aktier och röster i Ascelia Pharma AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-13 | Ascelia Pharma | Kommuniké från extra bolagsstämma den 13 november 2023 i Ascelia Pharma AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-13 | Ascelia Pharma | Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 13 November 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-09 | Ascelia Pharma | Ascelia Pharma resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-09 | Ascelia Pharma | Ascelia Pharma beslutar om omvandling av C-aktier till stamaktier för leverans till deltagare i incitaments-program | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-09 | Penser Access | Penser Access: Blickarna mot maj - Ascelia Pharma | Pressreleaser | Visa Stäng |
|
||||
2023-11-09 | Redeye | Redeye: Ascelia Q3 update - On track for a SPARKLE result in May 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-08 | Ascelia Pharma | QUARTERLY REPORT Q3 2023: Re-evaluation of SPARKLE Phase 3 Study Images Progresses According to Plan | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-08 | Ascelia Pharma | KVARTALSRAPPORT Q3 2022: Den ny utläsning av bilderna från fas 3-studien SPARKLE fortskrider enligt planen | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-10-19 | Ascelia Pharma | NOTICE OF EXTRAORDINARY GENERAL MEETING IN ASCELIA PHARMA AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-19 | Ascelia Pharma | KALLELSE TILL EXTRA BOLAGSSTÄMMA I ASCELIA PHARMA AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-04 | Ascelia Pharma | Ascelia Pharma får översiktsartikel om Orviglance accepterad för publicering i Investigative Radiology | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-04 | Ascelia Pharma | Ascelia Pharma Gets Acceptance for Publication of Orviglance Review Article in Investigative Radiology | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-18 | Redeye | Redeye: Ascelia Pharma - All attention on the top priority | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-13 | Ascelia Pharma | Ascelia Pharma to Reach Headline Results from SPARKLE Re-Evaluation by May 2024 with Current Funding | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-13 | Ascelia Pharma | Ascelia Pharma når headline-resultat från SPARKLE-utläsningen i maj 2024 med nuvarande finansiering | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-31 | Ascelia Pharma | Ascelia Pharma gör omfattande neddragning av organisationen för att nå headline-resultat med SPARKLE | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-31 | Ascelia Pharma | Ascelia Pharma significantly reduces organization to reach SPARKLE headline results | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-21 | Penser Access | Penser Access: I väntan på nästa milstolpe - Ascelia Pharma | Pressreleaser | Visa Stäng |
|
||||
2023-08-18 | Ascelia Pharma | Half-Year report 2023: Re-evaluation required after intra-reader inconsistency in scoring of images from phase 3 study SPARKLE | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-18 | Ascelia Pharma | Halvårsrapport 2023: Ny utläsning krävs efter intraläsarinkonsistens rörande poängsättning av bilder av läsare från fas 3-studien SPARKLE | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-09 | Ascelia Pharma | Ascelia Pharma provides clarifications around the intra-reader variability in read-out of images in the SPARKLE study | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-09 | Ascelia Pharma | Ascelia Pharma ger förtydliganden kring intraläsarvariabilitet vid utläsningen av bilder i SPARKLE-studien | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-09 | Penser Access | Penser Access: Oväntat utfall - Ascelia Pharma | Pressreleaser | Visa Stäng |
|
||||
2023-08-09 | Redeye | Redeye: Ascelia Pharma - SPARKLE is blurred | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-07 | Ascelia Pharma | Re-Evaluation Required After Intra-Reader Inconsistency in Scoring of Images from Phase 3 Study SPARKLE | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-07 | Ascelia Pharma | Ny utläsning krävs efter intraläsarinkonsistens rörande poängsättning av bilder av läsare från fas 3-studien SPARKLE | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-20 | Penser Access | Penser Access: Sanningens ögonblick - Ascelia Pharma | Pressreleaser | Visa Stäng |
|
||||
2023-06-16 | Ascelia Pharma | Ascelia Pharma presented Orviglance Hepatic Impairment Data and hosted a Q&A with liver imaging experts at the 2023 ESGAR Annual Meeting | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-16 | Ascelia Pharma | Vid ESGARs årsmöte 2023 presenterade Ascelia Pharma Orviglance-data från studien med nedsatt leverfunktion samt var värd för en Q&A med experter inom leveravbildning | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-15 | Redeye | Redeye: Ascelia Pharma - SPARKLE is about to sparkle | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-12 | Penser Access | Penser Access: Nyckelhändelse stundar - Ascelia Pharma | Pressreleaser | Visa Stäng |
|
||||
2023-05-11 | Ascelia Pharma | KVARTALSRAPPORT Q1 2023: Fas 3 studien för Orviglance, SPARKLE, sista patientens sista besök (Last Patient Last Visit, LPLV) har avslutats | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-11 | Ascelia Pharma | QUARTERLY REPORT Q1 2023: Orviglance phase 3 study, SPARKLE, Last Patient Last Visit (LPLV) has been completed | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-04 | Ascelia Pharma | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 4 May 2023 | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Bulletin from the Annual General Meeting in Ascelia Pharma AB on 4 May 2023Today, on 4 May 2023, an annual general meeting was held in Ascelia Pharma AB. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority. Resolution on adoption of accounts and allocation of the company’s result Discharge from liability for the members of the board members and the CEO Election and remuneration of the board of directors and auditors Furthermore, the annual general meeting resolved that remuneration to the board of directors shall be paid with SEK 525,000 to the chairman of the board and with SEK 262,500 to each of the other board members who are not employed by the company. It was further resolved that remuneration for committee work shall be paid with SEK 100,000 to the chairman of the Audit Committee, with SEK 25,000 to each of the other members of the Audit Committee, with SEK 100,000 to the chairman of the Commercialization Committee, with SEK 25,000 to each of the other members of the Commercialization Committee, with SEK 50,000 to the chairman of the Remuneration Committee and with SEK 25,000 to each of the other members of the Remuneration Committee. Furthermore, it was resolved that board members residing outside of Europe shall be paid additional board remuneration with SEK 10,000 per physical board meeting attended. Finally, the annual general meeting resolved to re-elect Öhrlings PricewaterhouseCoopers AB as auditor and that remuneration to the auditor shall be paid in accordance with customary norms and approved invoice. Öhrlings PricewaterhouseCoopers AB has informed that the authorized public accountant Carl Fogelberg will continue to be the auditor in charge. Resolution on remuneration of the Nomination Committee for work ahead of the annual general meeting in 2024 Resolution on approval of remuneration report Resolution on authorization for the board of directors regarding issues Resolution on implementation of a long-term incentive program by way of (A) implementation of a performance-based share saving program; (B) authorization on directed issues of series C shares; (C) authorization for repurchase of series C shares; and (D) resolution on transfer of own ordinary shares The maximum number of shares that can be issued in relation to LTI 2023 is 1,743,752, whereof 1,416,000 for delivery of Matching Shares and Performance Shares to the participants and in the aggregate 327,752 related to hedging of cash flow for social security payments, which corresponds to a dilution of approximately 4.92 per cent of the company’s ordinary shares after full dilution, calculated on the number of ordinary shares that will be added upon full issuance of shares in connection with LTI 2023. In order to secure the company’s delivery of Matching Shares and Performance Shares to the participants under LTI 2023, the annual general meeting also resolved (i) to authorize the board of directors to resolve on directed issues of series C shares, whereby the new shares, with deviation from the shareholders’ preferential rights, only may be subscribed for by a bank or a securities company at a subscription price which corresponds to the quota value of the shares; (ii) to authorize the board of directors to resolve to repurchase own series C shares; and (iii) to approve transfer of own ordinary shares to the participants under LTI 2023. Resolution on authorization for the board of directors regarding transfer of own ordinary shares |
||||
2023-05-04 | Ascelia Pharma | Kommuniké från årsstämma den 4 maj 2023 i Ascelia Pharma AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-25 | Ascelia Pharma | Studie av nedsatt leverfunktion (Hepatic Impairment Study) accepterad för presentation vid större radiologi- och leverkonferenser | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-25 | Ascelia Pharma | Hepatic Impairment Study Accepted for Presentation at Major Radiology and Liver Conferences | Pressreleaser | Ladda ner | Visa Stäng |
|